12 results on '"Samiran Panda"'
Search Results
2. Tuberculosis
- Author
-
Samiran Panda
- Subjects
General Medicine ,General Biochemistry, Genetics and Molecular Biology - Published
- 2023
3. Community voices around COVID-19 vaccine in Chennai, India
- Author
-
Muthusamy Santhosh, Kumar, Jayaprakasam, Madhumathi, K, Gayathri, Amanda G, A Rozario, R, Vijayaprabha, M, Balusamy, Harshal, Sonekar, and Samiran, Panda
- Subjects
Vaccines ,COVID-19 Vaccines ,Vaccination ,Humans ,India ,COVID-19 ,General Medicine ,Pandemics ,Qualitative Research ,General Biochemistry, Genetics and Molecular Biology - Abstract
Globally, vaccination is considered as an important public health strategy to mitigate the impact of the COVID-19 pandemic. The purpose of the current study was to conduct an in-depth inquiry to explore perceptions of community members around COVID-19 vaccines in the southern city of Chennai, Tamil Nadu. This was conducted during the early phase of the vaccine rollout programme in India.A qualitative investigation was conducted between January-February 2021 through in-depth interviews. Healthcare workers, religious leaders, community influencers, local administrators and representatives of marginalized communities were included. The key informant interview guides and probes explored five domains; (i) vaccine availability, (ii) trust in COVID-19 vaccines, (iii) vaccine-related concerns, (iv) health/risk balance and (v) vaccine prioritization. Transcripted interviews were coded using a thematic approach and analyzed manually as well as with the help of ATLAS.ti 9 software.Eagerness to receive COVID-19 vaccines amongst some of the respondents was linked with freedom from fear, possible restoration of normalcy, protection of family and ability to travel and work abroad. Concerns around threat of emergence of new variants, damage caused by such viral mutants and trust in policymakers were other facilitatory influencers for vaccine uptake. On the other hand, doubts surrounding safety and fear of side effects of COVID-19 vaccine were the feeders to vaccine hesitancy. Lack of accurate information, sensational media reports and rumours exacerbated this fear and provoked anxiety among people. Apprehensions around COVID-19 vaccine in the wake of its rapid development and approval for use and reluctance to take it during the declining phase of the epidemic were identified as other inhibitory factors. Participants underlined the importance of having responsive communication strategies in place focussing on vaccine safety. Making vaccines available to people free of cost and ensuring wider access were other programmatic suggestions.In conclusion, our study findings suggest that it is essential to remain engaged with communities and execute evidence-based information dissemination strategy about the safety and efficacy of the vaccines. We identified that it is also imperative to sensitize and train media professionals on how to report side effects related to vaccines. Responsive communication strategies will thus have the potential to serve as a key public health approach pertaining to future pandemic preparedness as well as to manage the demands of clinical and public health issues in an ongoing pandemic situation.
- Published
- 2022
4. Author′s response
- Author
-
Aparna Mukherjee, Gunjan Kumar, RavendraK Sharma, GeethaR Menon, Damodar Sahu, Naveet Wig, Samiran Panda, VishnuVardhan Rao, Sujeet Singh, Randeep Guleria, and Balram Bhargava
- Subjects
General Medicine ,General Biochemistry, Genetics and Molecular Biology - Published
- 2021
5. HIV epidemic in Mizoram, India: A rapid review to inform future responses
- Author
-
Amrita Rao, Megha Mamulwar, SheikhMohammed Shahabuddin, Tarun Roy, Nunui Lalnuntlangi, and Samiran Panda
- Subjects
General Medicine ,General Biochemistry, Genetics and Molecular Biology - Published
- 2022
6. Development & validation of scales to assess stigma related to COVID-19 in India
- Author
-
MVishnu Vardhana Rao, Saritha Nair, Aparna Joshi, Sumit Aggarwal, Tulsi Adhikari, Nupur Mahajan, Vishal Diwan, A Stephen, KRekha Devi, BijayaKumar Mishra, GirijeshKumar Yadav, Rewa Kohli, Damodar Sahu, BalKishan Gulati, Saurabh Sharma, Jeetendra Yadav, Senthanro Ovung, Chetna Duggal, Moina Sharma, SampadaDipak Bangar, Rushikesh Andhalkar, PricillaB Rebecca, S Rani, Pradeep Selvaraj, GladstonG Xavier, Vanessa Peter, Basilea Watson, T Kannan, KS MD. Asmathulla, Debdutta Bhattacharya, Jyotirmayee Turuk, SubrataKumar Palo, Srikanta Kanungo, AjitKumar Behera, AshokKumar Pandey, Kamran Zaman, BrijRanjan Misra, Niraj Kumar, SthitaPragnya Behera, Rajeev Singh, AbuHasan Sarkar, Kanwar Narain, Rajni Kant, Seema Sahay, RajnarayanRamshankar Tiwari, BeenaElizabeth Thomas, and Samiran Panda
- Subjects
Psychometrics ,Surveys and Questionnaires ,Social Stigma ,COVID-19 ,Humans ,India ,Reproducibility of Results ,General Medicine ,Pandemics ,General Biochemistry, Genetics and Molecular Biology - Abstract
COVID-19 pandemic has triggered social stigma towards individuals affected and their families. This study describes the process undertaken for the development and validation of scales to assess stigmatizing attitudes and experiences among COVID-19 and non-COVID-19 participants from the community.COVID-19 Stigma Scale and Community COVID-19 Stigma Scale constituting 13 and six items, respectively, were developed based on review of literature and news reports, expert committee evaluation and participants' interviews through telephone for a multicentric study in India. For content validity, 61 (30 COVID-19-recovered and 31 non-COVID-19 participants from the community) were recruited. Test-retest reliability of the scales was assessed among 99 participants (41 COVID-19 recovered and 58 non-COVID-19). Participants were administered the scale at two-time points after a gap of 7-12 days. Cronbach's alpha, overall percentage agreement and kappa statistics were used to assess internal consistency and test-retest reliability.Items in the scales were relevant and comprehensible. Both the scales had Cronbach's α above 0.6 indicating moderate-to-good internal consistency. Test-retest reliability assessed using kappa statistics indicated that for the COVID-19 Stigma Scale, seven items had a moderate agreement (0.4-0.6). For the Community COVID-19 Stigma Scale, four items had a moderate agreement.Validity and reliability of the two stigma scales indicated that the scales were comprehensible and had moderate internal consistency. These scales could be used to assess COVID-19 stigma and help in the development of appropriate stigma reduction interventions for COVID-19 infected, and mitigation of stigmatizing attitudes in the community.
- Published
- 2022
7. Looking back to move forward: A travel rule underlined by the current pandemic
- Author
-
Samiran Panda
- Subjects
General Medicine - Published
- 2022
8. Authors' response
- Author
-
Nivedita Gupta, Labanya Mukhopadhyay, PragyaD Yadav, Sreelekshmy Mohandas, DeepakY Patil, Anita Shete-Aich, Samiran Panda, and Balram Bhargava
- Subjects
Medicine ,General Medicine ,General Biochemistry, Genetics and Molecular Biology - Published
- 2021
9. Author's response
- Author
-
Aparna Mukherjee, Gunjan Kumar, RavendraK Sharma, GeethaR Menon, Damodar Sahu, Naveet Wig, Samiran Panda, VishnuVardhan Rao, Sujeet Singh, Randeep Guleria, Balram Bhargava, and null National Clinical Registry for COVID Team
- Subjects
Hospitalization ,Male ,Author's Response ,SARS-CoV-2 ,COVID-19 ,Humans ,Medicine ,Registries ,General Medicine ,Pandemics ,General Biochemistry, Genetics and Molecular Biology - Abstract
India witnessed a massive second surge of COVID-19 cases since March 2021 after a period of decline from September 2020. Data collected under the National Clinical Registry for COVID-19 (NCRC) were analysed to describe the differences in demographic and clinical features of COVID-19 patients recruited during these two successive waves.The NCRC, launched in September 2020, is an ongoing multicentre observational initiative, which provided the platform for the current investigation. Demographic, clinical, treatment and outcome data of hospitalized, confirmed COVID-19 patients were captured in an electronic data portal from 41 hospitals across India. Patients enrolled during September 1, 2020 to January 31, 2021 and February 1 to May 11, 2021 constituted participants of the two successive waves, respectively.As on May 11, 2021, 18961 individuals were recruited in the registry, 12059 and 6903 reflecting in-patients from the first and second waves, respectively. Mean age of the patients was significantly lower in the second wave [48.7 (18.1) yr vs. 50.7 (18.0) yr, P0.001] with higher proportion of patients in the younger age group intervals of20, and 20-39 yr. Approximately 70 per cent of the admitted patients were ≥ 40 yr of age in both waves of the pandemic. The proportion of males were slightly lower in second wave as compared to the first [4400 (63.7%) vs. 7886 (65.4%), P=0.02]. Commonest presenting symptom was fever in both waves. In the second wave, a significantly higher proportion [2625 (48.6%) vs. 4420 (42.8%), P0.003] complained of shortness of breath, developed ARDS [422(13%) vs. 880 (7.9%), P0.001], required supplemental oxygen [1637 (50.3%) vs. 4771 (42.7%), P0.001], and mechanical ventilation [260 (15.9%) vs. 530 (11.1%), P0.001]. Mortality also significantly increased in the second wave [OR: 1.35 (95% CI: 1.19, 1.52)] in all age groups except in20 yr.The second wave of COVID-19 in India was slightly different in presentation than the first wave, with a younger demography, lesser comorbidities, and presentation with breathlessness in greater frequency.
- Published
- 2021
10. Comparison of the immunogenicity & protective efficacy of various SARS-CoV-2 vaccine candidates in non-human primates
- Author
-
Nivedita Gupta, Sreelekshmy Mohandas, Balram Bhargava, Deepak Y. Patil, Samiran Panda, Anita Shete-Aich, Pragya D Yadav, and Labanya Mukhopadhyay
- Subjects
0301 basic medicine ,030106 microbiology ,non-human primate ,medicine.disease_cause ,immune response ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,vaccine ,Pandemic ,Medicine ,030212 general & internal medicine ,Neutralizing antibody ,Coronavirus ,biology ,business.industry ,Immunogenicity ,COVID-19 ,neutralizing antibody ,inactivated vaccine ,General Medicine ,biology.organism_classification ,Clinical trial ,Rhesus macaque ,T-cell response ,Inactivated vaccine ,Immunology ,biology.protein ,Systematic Review ,business ,protein subunit vaccine ,covid-19 - immune response - inactivated vaccine - neutralizing antibody - non-human primate - protein subunit vaccine - t-cell response - vaccine - viral clearance ,viral clearance - Abstract
Background & objectives: The COVID-19 pandemic has emerged as a global public health crisis and research groups worldwide are engaged in developing vaccine candidates to curb its transmission, with a few vaccines having progressed to advanced stages of clinical trials. The aim of this systematic review was to compare immunogenicity and protective efficacy of various SARS-CoV-2 vaccine candidates tested in non-human primate (NHP) models. Methods: Literature on effect of SARS-CoV-2 vaccines in NHP models reported on PubMed and preprint platforms (medRxiv and bioRxiv) till October 22, 2020, was searched with the following terms: coronavirus vaccine, COVID-19 vaccine, SARS-CoV-2 vaccine, nonhuman primate, and rhesus macaque. Results: Our search yielded 19 studies, which reported immune response elicited by 18 vaccine candidates in NHP. All the vaccines induced detectable neutralizing antibody (NAb) titres in the serum of vaccinated animals, with some showing effective viral clearance from various organs. The vaccinated animals also showed nil to mild histopathological changes in their lungs compared to placebo groups in the trials that performed necropsy. Interpretation & conclusions: Our findings highlighted onset of quick immunogenicity and protective efficacy of mRNA-1273, followed by Ad26.CoV2.S, NVX-CoV2373, BNT162b2, RBD and BBV152 vaccine candidates in preclinical trials as compared to the others. NHP data also showed correlation with clinical trial data available for a few vaccines. Preclinical trials of COVID-19 vaccine candidates in NHPs yielded promising results, with some candidates faring better than others.
- Published
- 2021
11. Authors′ response
- Author
-
Samiran Panda, Pranab Chatterjee, Tanu Anand, KhJitenkumar Singh, Reeta Rasaily, Ravinder Singh, Santasabuj Das, Harpreet Singh, Ira Praharaj, RamanR Gangakhedkar, and Balram Bhargava
- Subjects
lcsh:R ,lcsh:Medicine ,General Medicine ,General Biochemistry, Genetics and Molecular Biology - Published
- 2020
12. Authors′ response
- Author
-
Samiran Panda, Pranab Chatterjee, Tanu Anand, KhJitenkumar Singh, Reeta Rasaily, Ravinder Singh, Santasabuj Das, Harpreet Singh, Ira Praharaj, RamanR Gangakhedkar, and Balram Bhargava
- Subjects
SARS-CoV-2 ,Health Personnel ,lcsh:R ,Correspondence ,lcsh:Medicine ,COVID-19 ,Humans ,India ,General Medicine ,Pandemics ,General Biochemistry, Genetics and Molecular Biology ,Time - Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.